Doctors Could Share Costs of GP Courses With Pharmaceutical Companies

Continuing Medical Education (CME) is the systema role in the training of physicians, and that
by which doctors in the UK keep their skills anddoctors should take more responsibility for their
knowledge up to date throughout theirown professional development.
professional careers. If new proposals currentlyAlthough the proposals were originally put forward
being considered come into effect, the system byby the RCP, the ABPI wishes to push ahead with
which CME is funded could undergo a sea change.them on its own terms, rather than have similar
Currently, many CME courses and events arearrangements forced upon its members in the
funded by the big pharmaceutical companies.future.
Critics of the present system feel that this givesDespite the VITA Agenda and the good intentions
such companies an undue influence overbehind it, it is likely that relations between the
physicians and may affect the choice of drugsdrug companies and the medical profession will
they prescribe to their patients.never be straightforward, simply because the two
If new proposals come to fruition, however, thegroups have such different aims and agendas.
cost of CME could be split 50-50 between theIn an extensive consultation on CME, the RCP
drug industry and the doctors themselves.gathered a wide spectrum of opinions from its
Currently, doctors are given an annual budget formembers, with some believing that the influence
training from the NHS, and under these proposals,of the pharmaceutical companies on training
this is where the doctor's contribution would comeproduced an unhealthy influence on doctors, while
from.others thought that the involvement of the
The Association of the British Pharmaceuticalindustry was a positive factor which helped them
Industry (ABPI) put forward the proposals underfind out about new products.
its "VITA Agenda", a new initiative that is intendedABPI is still in consultation with its members about
to promote trust and openness in thethe new proposals, but, once this stage is
pharmaceutical industry, and to foster bettercompleted, it will open up the issue to wider
relations between the industry, the medicaldebate beyond the industry. Any initiatives that
profession and the public as a whole.are agreed between its members will then
The Royal College of Physicians (RCP), one of thebecome integrated into the new ABPI code at
UK's leading medical organisations, has also statedsome point in the coming year.
that pharmaceutical companies should play less of